BDMD News & Events

Baird Medical announced a strategic partnership with Stonewood Key Capital, a wholly-owned comprehensive investment management enterprise from New Zealand. This collaboration positions the Hainan Free Trade Port as a pivotal hub for the company's cross-border operations and supply chain. By capitalizing on the Free Trade Port's policies regarding cross-border capital flows and personnel mobility, the company aims to secure a competitive operational framework designed to meet rising demand for minimally invasive therapies addressing thyroid and other soft tissue applications.

Baird Medical announced it has reached key regulatory milestones with official product registrations from both the Medical Device Board of Pakistan and the Ministry of Health of Vietnam. In Pakistan, the company successfully executed its official product launch at the Armed Forces Institute of Radiology & Imaging. The launch was conducted under the professional guidance of Dr. Raza Raheem, a leading authority in the country's interventional radiology sector. Simultaneously, the registration approval in Vietnam marks a significant expansion of Baird Medical's compliant footprint within the Southeast Asian market. These dual approvals underscore the company's commitment to accelerating its global commercialization strategy.

Baird Medical Investment Holdings announced the establishment of a dedicated manufacturing base in the U.S. The decision to anchor production in North America is driven by the Company's rapid commercial success across over a dozen countries, including recent significant market penetrations in Indonesia and Malaysia. To support this international footprint, Baird Medical has partnered with California-based MPS Medical to create a centralized production hub. This facility is designed to supply Baird Medical's advanced proprietary technologies to global markets, ensuring the highest standards of quality and supply chain efficiency for its expanding client base.

Baird Medical announced a milestone in its international expansion. The FDA has issued a Certificate to Foreign Government to the Egyptian regulatory authorities, affirming the company's compliance with U.S. medical device standards and facilitating its market entry into Egypt. Simultaneously, Baird Medical has formally submitted regulatory registration applications in Egypt, Hong Kong, Thailand, Malaysia, Kazakhstan, Sri Lanka, and India. The company anticipates timely approvals in these markets. This follows the regulatory approval in Indonesia in March. In preparation for market entry, Baird Medical has initiated partnerships with healthcare institutions across these regions to establish distribution networks and conduct training programs on microwave ablation procedures. Microwave ablation is a minimally invasive procedure widely used in the treatment of thyroid nodules and tumors.